DHODH-IN-17

Cat. No.: HY-128068

CAS No.: 16344-26-6

Molecular Formula: $C_{12}H_9ClN_2O_2$

Molecular Weight: 248.67

Target: Dihydroorotate Dehydrogenase

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 83.33 mg/mL (335.10 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	4.0214 mL	20.1070 mL	40.2139 mL
	5 mM	0.8043 mL	4.0214 mL	8.0428 mL
	10 mM	0.4021 mL	2.0107 mL	4.0214 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (8.36 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1.67 mg/mL (6.72 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1.67 mg/mL (6.72 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor (IC_{50}=0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML)[1].

IC_{50} & Target

IC50: 0.4 μM (DHODH)[1]

In Vitro

DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor with an IC_{50} value of 0.40 μM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lewis TA, et al. Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia. ACS Med Chem Lett. 2016;7(12):1112-1117.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA